Ami Ranani
Optometrist · Somers, NYNPI 1306841838
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (56.9%), speaking fees and consulting fees — rather than concentrated in one kind of arrangement. 25 manufacturers reported payments, led by Alcon at 28.7% of the total. Reporting peaked in 2019 at $6,320 and has fallen 95.3% since, to $297 in 2025. Among optometrist clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 209 payments — averaging $56.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$3K
- Coopervision Inc.$2K
- Eyevance Pharmaceuticals LLC$2K
- AbbVie$971
- Oyster Point Pharma, Inc.$444
- Bausch & Lomb, A Division Of Bausch Health US, LLC$407
- plus $2K from 19 others
What the payments were for
- Consulting fees$1,58013%
- Speaking & faculty fees$2,44120%
- Travel & lodging$1,1189%
- Food & beverage$6,77257%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 43 | $3,424 |
| Coopervision Inc. | 15 | $2,371 |
| Eyevance Pharmaceuticals LLC | 20 | $1,802 |
| AbbVie(2 entities) | 41 | $971 |
| Oyster Point Pharma, Inc. | 7 | $444 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 11 | $407 |
| Visioneering Technologies, Inc. | 9 | $330 |
| Mallinckrodt Hospital Products Inc. | 2 | $247 |
| Bausch & Lomb Americas Inc. | 9 | $246 |
| Shire North American Group Inc | 3 | $229 |
| Biotissue Holdings Inc. | 6 | $204 |
| Sun Pharmaceutical Industries Inc. | 12 | $200 |
| Sight Sciences, Inc. | 6 | $199 |
| Kala Pharmaceuticals, Inc. | 4 | $182 |
| Novartis | 7 | $155 |
| Rxsight Inc | 1 | $134 |
| Glaukos Corporation | 1 | $125 |
| Johnson & Johnson Vision Care, Inc. | 4 | $77 |
| Tarsus Pharmaceuticals, Inc. | 1 | $36 |
| Carl Zeiss Meditec USA, Inc. | 1 | $30 |
| ABB Con-cise Optical Group LLC | 2 | $27 |
| Harrow Eye, LLC | 1 | $19 |
| Carl Zeiss Meditec, Inc. | 1 | $18 |
| Quidel Corporation | 1 | $18 |
| Amgen | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DAILIES$2,132
- Multiple Brands Contact Lens$1,677
- Zerviate$1,338
- AIR OPTIX$865
- TYRVAYA$254
- ACTHAR$247
- XIIDRA$245
- RESTASIS$225
- Flarex$150
- RXSIGHT CONTACT LENS$134
- RXSIGHT INJECTOR CARTRIDGE$134
- RXSIGHT INJECTOR HANDPIECE$134
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$134
- LIGHT ADJUSTABLE LENS (LAL)$134
- iStent Trabecular Micro-Bypass Stent System$125
- iStent inject Trabecular Micro-Bypass Stent System$125
- BIOTRUE$125
- ULTRA$125
- BIOTRUE ONE DAY$125
- EYSUVIS$125
How this compares
$11,910 in reported general payments places this provider in the 95th percentile of 2,743 optometrist providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 60 | $36,951 |
| RestasisCyclosporine | 26 | $36,305 |
| XiidraLifitegrast | 13 | $11,131 |
| VyzultaLatanoprostene Bunod | 19 | $10,010 |
| CombiganBrimonidine Tartrate/Timolol | 14 | $5,546 |
| Latanoprost | 72 | $1,133 |
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 20 | $850 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 12 | $350 |
| Timolol Maleate | 29 | $214 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Restasis, Combigan | $971 | $78,802100 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta | $246 | $21,14132 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,743 optometrist providers in New York.
Other optometrist in Somers
- Roy KlineLake Katrine$822K
- Susan ResnickNew York$463K
- Murray FingeretHewlett$374K
- Albert MorierSlingerlands$347K
- Denise WhittamNew York$343K
- Justin BazanBrooklyn$303K
- Jennifer TsaiNew York$275K
- Alexander KabiriQueens Village$268K
- Sophia VisanjiNew York$233K
- Jason ComptonNew York$181K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.